arrow
S

Serena Garufi

asp ct—po paternò
H指数:13
被引数:358

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis—A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

美基珠单抗在溃疡性结肠炎中的诱导和延长诱导治疗——来自西西里炎症性肠病网络(SN-IBD)的前瞻性真实世界研究

2026-07-300
OAAI
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease
2022-05-019
PRE
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501

SPOSAB ABP 501: 阿达木单抗生物仿制药ABP 501治疗炎症性肠病患者的西西里前瞻性观察研究

2021-07-0319
PREAI
SPOSAB ABP 501-A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
2021-05-270
PRE
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis

维多珠单抗、阿达木单抗和戈利木单抗在溃疡性结肠炎患者中的倾向评分加权比较

2020-12-0120
PREAI
Effectiveness and safety of vedolizumab in biologically naive patients: A real-world multi-centre study

维多珠单抗在生物幼稚患者中的有效性和安全性: 一项真实世界的多中心研究

2020-11-0130
OAAI
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2020-10-0911
PREAI
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease
2020-06-0818
PREAI
Effectiveness of very low-volume preparation for colonoscopy: A prospective, multicenter observational study
2020-04-2838
OAAI
ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) ARE LESS LIKELY TO PERSIST ON ANTI-TNF THERAPY COMPARED WITH YOUNGER PATIENTS. DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)
2019-03-010
PREAI
Elderly patients with inflammatory bowel disease (IBD) are less likely to persist on anti-TNF therapy compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2019-01-250
PREAI